Acorda Therapeutics Inc
Most Recent
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
A Look at Alkermes’ Diabetes Product Portfolio
According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.
